Key Points Question Is short-term oral rivaroxaban a noninferior alternative to parenteral enoxaparin in the acute phase of acute coronary syndrome (ACS)? Findings This equivalence and noninferiority trial including 2046… Click to show full abstract
Key Points Question Is short-term oral rivaroxaban a noninferior alternative to parenteral enoxaparin in the acute phase of acute coronary syndrome (ACS)? Findings This equivalence and noninferiority trial including 2046 patients found that short-term rivaroxaban 5 mg twice daily was noninferior to enoxaparin in terms of bleeding risk and efficacy in reducing major adverse cardiovascular events during 6 months of follow-up among patients with ACS who missed the primary reperfusion window and before selective revascularization. Meaning These findings suggest that rivaroxaban-5 mg twice daily may be a reasonable alternative to enoxaparin in the acute phase of ACS, which may provide useful information for designing future definitive randomized clinical trials with sufficient sample sizes.
               
Click one of the above tabs to view related content.